Aclaris Therapeutics Expands Leadership Team
February 01 2022 - 4:01PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced the
appointment of James Loerop as Chief Business Officer, effective
January 31, 2022.
“We are excited to welcome Jim to Aclaris,” said Dr. Neal
Walker, President and CEO of Aclaris. “His experience as a business
development leader in the life sciences industry will be extremely
valuable in executing our global business development strategy for
our drug development pipeline.”
Mr. Loerop brings over two decades of experience leading global
business development in the life sciences industry. Mostly
recently, he served as Executive Vice President, Business
Development and Strategic Planning at Anika Therapeutics, Inc.
Prior to that, Mr. Loerop held senior leadership roles at various
companies in the pharmaceutical and life sciences industry,
including Lupin Pharmaceuticals, Inc., Alexion Pharmaceuticals,
Inc., GlaxoSmithKline, and Stiefel Laboratories, Inc. prior to its
acquisition by GSK.
“I am thrilled to join the Aclaris team,” said Mr. Loerop.
“Aclaris has done a tremendous job at developing a pipeline of
novel drug candidates for immuno-inflammatory diseases, and I look
forward to leveraging my experience to assist in furthering
Aclaris’ overall corporate strategy.”
Aclaris also welcomes the addition of John Schindler, Ph.D., as
Senior Director, Discovery Research. Dr. Schindler will be leading
efforts to identify and develop early stage discovery targets. Dr.
Schindler has over 20 years of research experience building and
directing drug discovery teams in immunology, cancer, diabetes,
immunology-oncology, and neurodegeneration. Dr. Schindler has
previously held scientific leadership positions at Eli Lilly and
Company and Pfizer Inc., most recently serving as a director at Eli
Lilly where he led its early portfolio discovery efforts.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris’ current beliefs
and expectations. These forward-looking statements include the
future contributions of Mr. Loerop and Dr. Schindler. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include uncertainties inherent in the conduct
of clinical trials, Aclaris’ reliance on third parties over which
it may not always have full control, Aclaris’ ability to enter into
strategic partnerships on commercially reasonable terms, the
uncertainty regarding the COVID-19 pandemic and other risks and
uncertainties that are described in the Risk Factors section of
Aclaris’ Annual Report on Form 10-K for the year ended December 31,
2020 and other filings Aclaris makes with the U.S. Securities and
Exchange Commission from time to time. These documents are
available under the “SEC Filings” page of the “Investors” section
of Aclaris’ website at www.aclaristx.com. Any forward-looking
statements speak only as of the date of this press release and are
based on information available to Aclaris as of the date of this
release, and Aclaris assumes no obligation to, and does not intend
to, update any forward-looking statements, whether as a result of
new information, future events or otherwise.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024